Physician profile
Keith A Meritz
NPI 1801956974
$778.84
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $27.21 · 2021: $93.02 · 2022: $444.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zap Surgical Systems, INC. | $508.76 | 2021-2022 | |
| Janssen Biotech, INC. | $122.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.94 | 2019-2020 | |
| Reflexion Medical, INC. | $28.52 | 2021 | |
| Dendreon Pharmaceuticals LLC | $19.73 | 2019 | |
| Gilead Sciences, INC. | $18.19 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.57 | 2019 | |
| Astellas Pharma US INC | $12.79 | 2019 | |
| Amgen INC. | $12.65 | 2019 | |
| Abbvie INC. | $12.21 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Meritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.